Clinical trial
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the…
NCT00050596 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00050596 |
|---|---|
| Title | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer |
| Official title | A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose of Docetaxel in Patients With Hormone-Refractory Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | MDX-010 / MDX-010 + Docetaxel |
| Start date | Nov 1, 2002 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Dec 17, 2002 |
| Last update posted | Jun 27, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: